{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T04:02:53Z","timestamp":1746417773358,"version":"3.40.4"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:00:00Z","timestamp":1616716800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Dual anti-platelet therapy (DAPT) with aspirin and clopidogrel has been the mainstay of treatment for patients with acute coronary syndrome (ACS). However, the recurrence of thrombotic events, potential aspirin and clopidogrel hypo-responsiveness, and other limitations of DAPT have led to the development of newer oral anti-thrombotic drugs. Apixaban, a new non-vitamin K antagonist, has been approved for use. In this meta-analysis, we aimed to compare the bleeding outcomes observed with the addition of apixaban to DAPT for the treatment of patients with ACS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Online databases including EMBASE, Cochrane Central, http:\/\/www.ClinicalTrials.gov, MEDLINE and Web of Science were searched for English based publications comparing the use of apixaban added to DAPT for the treatment of patients with ACS. Different categories of bleeding events and cardiovascular outcomes were assessed. The analysis was carried out by the RevMan software version 5.4. Odds ratios (OR) with 95% confidence intervals (CI) were used to represent the data following analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>This research analysis consisted of 4 trials with a total number of 9010 participants. Thrombolysis in myocardial infarction (TIMI) defined major bleeding (OR: 2.45, 95% CI: 1.45\u20134.12; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.0008), TIMI defined minor bleeding (OR: 3.12, 95% CI: 1.71\u20135.70; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.0002), International society of thrombosis and hemostasis (ISTH) major bleeding (OR: 2.49, 95% CI: 1.80\u20133.45; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.00001) and Global Use of Strategies to Open Occluded Arteries (GUSTO) defined severe bleeding (OR: 3.00, 95% CI: 1.56\u20135.78; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.01) were significantly increased with the addition of apixaban to DAPT versus DAPT alone in these patients with ACS. However fatal bleeding (OR: 10.96, 95% CI: 0.61\u2013198.3; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.11) was not significantly different.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Addition of the novel oral anticoagulant apixaban to the DAPT regimen significantly increased bleeding and therefore did not show any beneficial effect in these patients with ACS. However, due to the extremely limited data, we apparently have to rely on future larger studies to confirm this hypothesis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000025185","type":"journal-article","created":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T19:43:11Z","timestamp":1616528591000},"page":"e25185","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Increased bleeding events with the addition of apixaban to the dual anti-platelet regimen for the treatment of patients with acute coronary syndrome"],"prefix":"10.1097","volume":"100","author":[{"given":"Jing","family":"Jin","sequence":"first","affiliation":[{"name":"Department of Cardiology, The Fourth Hospital of Changsha, Changsha, Hunan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6142-4021","authenticated-orcid":false,"given":"Xiaojun","family":"Zhuo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital of Northwestern Polytechnical University, Xi an, Shanxi"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mou","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Fourth Hospital of Changsha, Changsha, Hunan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiming","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Fourth Hospital of Changsha, Changsha, Hunan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linlin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Fourth Hospital of Changsha, Changsha, Hunan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yashvina","family":"Devi Shamloll","sequence":"additional","affiliation":[{"name":"Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, PR China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,3,26]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.jacc.2011.08.007","article-title":"American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions. 2011\u200aACCF\/AHA\/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions","volume":"58","author":"Levine","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu278","article-title":"2014 ESC\/EACTS guidelines on myocardial revascularization: the Task Force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI)","volume":"35","author":"Windecker","year":"2014","journal-title":"Eur Heart J"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"e007754","DOI":"10.1161\/JAHA.117.007754","article-title":"More, More, More: reducing thrombosis in acute coronary syndromes beyond dual antiplatelet therapy-current data and future directions","volume":"7","author":"Spinthakis","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/j.jcin.2017.05.059","article-title":"Impact of aspirin and clopidogrel hyperresponsiveness in patients treated with drug-eluting stents: 2-year results of a prospective, multicenter registry study","volume":"10","author":"Stuckey","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3349\/ymj.2016.57.2.342","article-title":"Early experience of novel oral anticoagulants in catheter ablation for atrial fibrillation: efficacy and safety comparison to warfarin","volume":"57","author":"Shin","year":"2016","journal-title":"Yonsei Med J"},{"issue":"(suppl_G)","key":"R6-20250504","first-page":"G4","article-title":"Current practice and limitations of dual antiplatelet therapy in acute coronary syndrome","volume":"11","author":"Christian","year":"2009","journal-title":"Eur Heart J Suppl"},{"key":"R7-20250504","first-page":"97","article-title":"Evaluation of aspirin and clopidogrel resistance in patients with acute coronary syndrome by using adenosine diposphate test and aspirin test","volume":"29","author":"O","year":"2013","journal-title":"Pak J Med Sci"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2147\/VHRM.S6787","article-title":"Aspirin and clopidogrel hyperresponsiveness and nonresponsiveness in patients with coronary artery stenting","volume":"5","author":"Sharma","year":"2009","journal-title":"Vasc Health Risk Manag"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s12170-014-0430-5","article-title":"State-of-the-art: hypo-responsiveness to oral antiplatelet therapy in patients with type 2 diabetes mellitus","volume":"9","author":"Kumbhani","year":"2015","journal-title":"Curr Cardiovasc Risk Rep"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3132\/dvdr.2008.023","article-title":"Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents","volume":"5","author":"Arun","year":"2008","journal-title":"Diab Vasc Dis Res"},{"key":"R11-20250504","first-page":"209","article-title":"Response to clopidogrel and of the cytochrome CYP2C19 gene polymorphism","volume":"96","author":"Rim","year":"2018","journal-title":"Tunis Med"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s40264-015-0286-8","article-title":"Risks and benefits of triple oral anti-thrombotic therapies after acute coronary syndromes and percutaneous coronary intervention","volume":"38","author":"Alfredsson","year":"2015","journal-title":"Drug Saf"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.2147\/DDDT.S119616","article-title":"The clinical outcomes of triple antiplatelet therapy versus dual antiplatelet therapy for high-risk patients after coronary stent implantation: a meta-analysis of 11 clinical trials and 9553 patients","volume":"10","author":"Zhong-Guo","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/clc.22001","article-title":"The effectiveness and safety of triple-antiplatelet treatment based on cilostazol for patients receiving percutaneous coronary intervention: a meta-analysis","volume":"35","author":"Ping","year":"2012","journal-title":"Clin Cardiol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12872-015-0114-1","article-title":"Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Bundhun","year":"2015","journal-title":"BMC Cardiovasc Disord"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"e5581","DOI":"10.1097\/MD.0000000000005581","article-title":"Comparing the clinical outcomes in patients with atrial fibrillation receiving dual antiplatelet therapy and patients receiving an addition of an anticoagulant after coronary stent implantation: a systematic review and meta-analysis of observational studies","volume":"95","author":"Chaudhary","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2174\/157489006778777016","article-title":"Recent developments in antithrombotic therapy: will sodium warfarin be a drug of the past?","volume":"1","author":"Desai","year":"2006","journal-title":"Recent Pat Cardiovasc Drug Discov"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12872-016-0449-2","article-title":"Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis","volume":"17","author":"Bundhun","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"key":"R19-20250504","first-page":"9","article-title":"Apixaban (eliquis)--a new oral anticoagulant for atrial fibrillation","volume":"55","year":"2013","journal-title":"Med Lett Drugs Ther"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13643-017-0441-7","article-title":"Effect of standardized training on the reliability of the Cochrane risk of bias assessment tool: a prospective study","volume":"6","author":"da Costa","year":"2017","journal-title":"Syst Rev"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Subcommittee on control of anticoagulation of the scientific and standardization committee of the International society on thrombosis and haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ahj.2007.04.009","article-title":"Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs","volume":"154","author":"Steinhubl","year":"2007","journal-title":"Am Heart J"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1253\/circj.CJ-13-0209","article-title":"Randomized, double-blind trial to evaluate the safety of apixaban with antiplatelet therapy afteracute coronary syndrome in Japanese patients (APPRAISE-J)","volume":"77","author":"Ogawa","year":"2013","journal-title":"Circ J"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1161\/CIRCULATIONAHA.108.832139","article-title":"Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the apixaban for prevention of acute ischemic and safety events (APPRAISE) trial","volume":"119","author":"Alexander","year":"2009","journal-title":"Circulation"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ahj.2017.11.005","article-title":"Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: insights from the ARISTOTLE trial","volume":"197","author":"Kopin","year":"2018","journal-title":"Am Heart J"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.thromres.2015.03.032","article-title":"How the direct oral anticoagulant apixaban affects thrombin generation parameters","volume":"135","author":"Tripodi","year":"2015","journal-title":"Thromb Res"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/sj.bjp.0706743","article-title":"Mechanism of action of novel NO-releasing furoxan derivatives of aspirin in human platelets","volume":"148","author":"Turnbull","year":"2006","journal-title":"Br J Pharmacol"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/09537109876799","article-title":"Clopidogrel: a review of its mechanism of action","volume":"9","author":"Savi","year":"1998","journal-title":"Platelets"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jacc.2015.06.027","article-title":"Apixaban plus mono versus dual antiplatelet therapy in acute coronary syndromes: insightsFrom the APPRAISE-2 trial","volume":"66","author":"Hess","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.ahj.2014.12.022","article-title":"Anticoagulant therapy and outcomes in patients with prior or acute heart failure and acute coronary syndromes: insights from the apixaban for prevention of acute ischemic events 2 trial","volume":"169","author":"Cornel","year":"2015","journal-title":"Am Heart J"},{"key":"R33-20250504","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004310","article-title":"Use of chronic oral anticoagulation and associated outcomes among patients undergoing percutaneous coronary intervention","volume":"5","author":"Secemsky","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1161\/CIRCINTERVENTIONS.113.001150","article-title":"Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions","volume":"7","author":"Capodanno","year":"2014","journal-title":"Circ Cardiovasc Interv"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000025185","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:27:48Z","timestamp":1746340068000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000025185"}},"subtitle":["A meta-analysis"],"short-title":[],"issued":{"date-parts":[[2021,3,26]]},"references-count":34,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000025185","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2021,3,26]]},"assertion":[{"value":"2020-12-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}